ArticleArchives of Razi Institute2025
Riboceine Regimen Circumvents Reserpine-Induced Hepatotoxicity via the Modulation of Key Liver Function Markers in Adult Male Wistar Rats.
Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reserpine, an antipsychotic and antihypertensive medication, has been associated with liver damage and dysfunction. The present study examined the potential hepatoprotective effect of a riboceine regimen against reserpine-induced hepatotoxicity in adult male Wistar rats. A total of twenty-five adult male Wistar rats were randomly assigned to five groups: The following combinations were administered: control, Reserpine, Reserpine + Citalopram, Reserpine + Riboceine, and Reserpine + Citalopram + Riboceine. Liver function markers, including alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP), were analysed in serum samples in order to assess liver health. Furthermore, a histopathological examination of the liver tissue was conducted to visualise any morphological changes. Serum levels of ALT and AST increased significantly in rats administered reserpine in isolation in comparison with the control group, indicating hepatocellular damage. Conversely, the Riboceine + Reserpine group demonstrated a substantial decrease in ALT and AST levels in comparison to the Reserpine group, thereby indicating a protective effect of riboceine against reserpine-induced hepatotoxicity. No significant difference was observed in the serum level of ALP across the experimental groups. Histopathological examination confirmed the attenuated liver injury in the Riboceine + Reserpine group, with a reduction in necrotic areas and inflammation compared to the Reserpine group. The findings indicate that a riboceine regimen effectively circumvents reserpine-induced hepatotoxicity in adult male Wistar rats. The modulation of key liver function markers, in conjunction with histopathological evidence, substantiates the hepatoprotective role of riboceine in mitigating liver damage induced by reserpine. This study offers a number of promising insights into the potential therapeutic use of riboceine as a hepatoprotective agent. It could therefore be beneficial for patients undergoing treatment with reserpine or similar medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.